Table of Contents

Quick answer

An amylin receptor agonist is a medicine that copies amylin, a hormone your pancreas releases along with insulin after you eat. It helps you feel full sooner, slows how fast food leaves your stomach, and lowers blood sugar after meals. Only one, pramlintide (Symlin), is FDA-approved, and only for diabetes. Newer once-weekly versions such as eloralintide and cagrilintide are still in clinical trials for weight loss.

Takeaways

  • Amylin is a natural fullness hormone made by the same pancreatic cells that make insulin.
  • Amylin receptor agonists mimic it, which can mean smaller meals, slower stomach emptying and a smaller blood sugar rise after eating.
  • They are not GLP-1 drugs. They act on a different receptor, which is why researchers are testing them alone and alongside GLP-1 medicines.
  • In a 48-week Phase 2 trial, Eli Lilly’s eloralintide led to average weight loss of 9.5% to 20.1%, compared with 0.4% on placebo. It is now in Phase 3 and is not approved.
  • If you need treatment today, approved options such as Wegovy, Zepbound and Mounjaro are available with a prescription.

What Is an Amylin Receptor Agonist?

An amylin receptor agonist is a drug that switches on the same receptors your own amylin hormone uses. “Agonist” simply means something that activates a receptor, the way the right key turns a lock. When the drug locks on, your body responds as if it had released extra amylin after a meal.

Amylin receptors sit in several places, including parts of the brain that control how much you eat, according to a Cleveland Clinic review of amylin and pramlintide. That is why this drug class mainly affects appetite and fullness rather than burning fat directly.

Drugs in this class come in two styles. Selective agonists act mainly on amylin receptors. Non-selective agonists also act on calcitonin receptors, close relatives of the amylin receptor. Lilly’s discovery paper on eloralintide describes eloralintide as selective and cagrilintide as non-selective. In animal studies, eloralintide caused less nausea-like behavior than cagrilintide, but the two have not been compared head to head in people. Our guide to eloralintide vs cagrilintide covers the differences in detail.

What Is Amylin and What Does It Do?

Amylin is a small hormone, 37 amino acids long, that your pancreas releases at the same time as insulin when you eat. It comes from beta cells, the insulin-making cells in your pancreas, and it works alongside insulin to keep blood sugar steady after meals.

According to the Cleveland Clinic review, amylin has four main jobs:

  • Lowers glucagon after meals. Glucagon is a hormone that tells your liver to release stored sugar. Less glucagon means less sugar dumped into your blood after eating.
  • Slows stomach emptying. Food leaves your stomach more gradually, so sugar enters your blood more slowly.
  • Signals fullness. Amylin acts on the brain to help you feel satisfied with less food.
  • Reduces the blood sugar spike after meals. This is the combined result of the three effects above.

People with type 1 and type 2 diabetes make less amylin, and the shortfall tends to match how low their insulin is. Natural amylin is also sticky and unstable as a liquid, so it cannot be used as a medicine on its own. Drugmakers had to change its structure to create usable versions, starting with pramlintide.

How an Amylin Receptor Agonist Works

An amylin receptor agonist works mainly by making you feel full sooner and for longer, so you eat fewer calories. Lilly says eloralintide’s effect on calorie intake is likely driven by satiety, the feeling of fullness, according to its Phase 2 results announcement.

What an Amylin Receptor Agonist Does

What the drug doesWhat you may notice
Signals fullness in the brainSmaller portions and feeling satisfied sooner
Slows stomach emptyingFood stays with you longer; nausea is possible, especially early on
Lowers glucagon after mealsA smaller blood sugar rise after eating
Reduces calorie intake over timeGradual weight loss

The newer drugs differ from the original in one big way: how long they last. Pramlintide has a short half-life of about 48 minutes and is injected before major meals, according to the SymlinPen prescribing information on DailyMed. Eloralintide and cagrilintide are long-acting and are given once a week in trials.

That change matters for weight loss. In diabetes trials, pramlintide’s weight effect was modest, about 1.8 kg (4 lb) more than placebo in one pooled analysis cited by the Cleveland Clinic review. The weekly drugs have produced much larger losses, which is why the drug class is back in the headlines.

Is an Amylin Agonist the Same as a GLP-1 Drug?

No. An amylin receptor agonist copies a different hormone and acts on a different receptor from GLP-1 drugs. GLP-1 drugs such as semaglutide copy GLP-1, a hormone made in your gut. Tirzepatide acts on two gut hormone receptors, GIP and GLP-1.

Both types reduce appetite and slow the stomach, but through separate pathways. Lilly has said eloralintide could serve as an alternative to these incretin drugs, or be added to them for people who need more weight loss.

Amylin Agonists vs. Other Weight Loss Drug Types

Drug typeHormone it copiesExamplesStatus (October 2026)
GLP-1 receptor agonistGLP-1Semaglutide (Wegovy, Ozempic)FDA-approved
GIP and GLP-1 receptor agonistGIP and GLP-1Tirzepatide (Zepbound, Mounjaro)FDA-approved
Amylin receptor agonistAmylinPramlintide (Symlin); eloralintide; cagrilintidePramlintide approved for diabetes; others investigational
Amylin plus GLP-1 combinationAmylin and GLP-1CagriSema; EloraTZP (with tirzepatide)Investigational
GIP, GLP-1 and glucagon agonistThree hormonesRetatrutideInvestigational, not for sale

Retatrutide often comes up in the same news stories, but it is not an amylin drug. Lilly describes it as an investigational triple receptor agonist that acts on GIP, GLP-1 and glucagon receptors. It is not approved and not for sale. You can read more in our post on what retatrutide is.

Which Amylin Receptor Agonists Are Approved or in Trials?

As of October 28, 2026, only one amylin receptor agonist is FDA-approved, and it is approved for diabetes, not weight loss. Several weekly amylin drugs are in late-stage trials.

Amylin Receptor Agonists: Approved and in Trials

DrugCompanyHow it is givenWhere it stands
Pramlintide (Symlin)AstraZenecaInjection before major mealsFDA-approved for type 1 and type 2 diabetes in people who use mealtime insulin
EloralintideEli LillyOnce-weekly injection (in trials)Phase 3 trials ongoing; not approved
CagriSema (cagrilintide plus semaglutide)Novo NordiskOnce-weekly injection (in trials)Under FDA review; Novo expects a decision in Q4 2026; not approved
EloraTZP (eloralintide plus tirzepatide)Eli LillyWeekly injections (in trials)Phase 2b complete; Lilly plans to start Phase 3 in Q4 2026

CagriSema is the furthest along. In the 68-week REDEFINE 1 trial of cagrilintide and semaglutide, 3,417 adults with overweight or obesity lost an average of 20.4% of their body weight, compared with 3.0% on placebo. Novo Nordisk filed CagriSema with the FDA in December 2025 and, in a September 2026 update, said it still expects a decision in the fourth quarter of 2026. Our roundup of new weight loss drugs covers CagriSema alongside other drugs in development.

EloraTZP pairs eloralintide with tirzepatide. In a 48-week Phase 2b trial of 367 adults with obesity or overweight and type 2 diabetes, Lilly reported weight loss of up to 23.3% and greater weight and A1C reductions than tirzepatide 15 mg alone, according to its EloraTZP results announcement.

What Eloralintide Trials Have Shown So Far

In its Phase 2 trial, eloralintide led to average weight loss of 9.5% to 20.1% after 48 weeks, depending on the dose, compared with 0.4% on placebo. The study included 263 adults with obesity or overweight plus at least one weight-related health problem, none of whom had type 2 diabetes. Their average starting weight was 240.5 lb. The results were published in The Lancet’s 48-week eloralintide trial report.

Eloralintide Phase 2 Results at 48 Weeks

Trial groupAverage weight loss at 48 weeksAverage pounds lost
Eloralintide 1 mg9.5%22.5 lb
Eloralintide 3 mg12.4%29.3 lb
Eloralintide 6 mg17.6%41.2 lb
Eloralintide 9 mg20.1%47.0 lb
Stepped up from 6 mg to 9 mg19.9%46.3 lb
Stepped up from 3 mg to 6 mg to 9 mg16.4%39.2 lb
Placebo0.4%0.4 lb

Source: Eli Lilly Phase 2 results announcement, efficacy estimand.

Good to Know

The doses above come from a research study and are shown for information only. They are not dosing instructions, and there is no approved dose of eloralintide. Talk to your prescriber about any weight loss medicine before you start, stop or change it.

Lilly also reported improvements in waist size, blood pressure, cholesterol and other blood fats, blood sugar control, and markers of inflammation. The most common side effects were mild to moderate stomach symptoms and fatigue. These were more common at higher doses, less common when the dose was raised slowly, and similar to placebo at 1 mg and 3 mg. Our post on eloralintide side effects breaks these down by dose.

Keep the limits of this evidence in mind. It was one 48-week trial of 263 people, funded by Lilly. Larger Phase 3 trials, which Lilly says are under way, will show whether these results hold up and what longer-term safety looks like.

Are Amylin Receptor Agonists Safe?

Trials so far show that the main side effects of amylin receptor agonists are stomach-related, especially nausea, and that these are usually mild to moderate. Long-term safety for the new weekly drugs is not yet known because their Phase 3 trials are still running or under review.

Here is what the evidence shows for each drug that has data:

  • Pramlintide (Symlin): The SymlinPen prescribing information carries a boxed warning for severe low blood sugar when it is used with insulin, especially in type 1 diabetes. When this happens, it occurs within 3 hours of the injection. The label notes that pramlintide alone does not cause low blood sugar.
  • CagriSema: In REDEFINE 1, stomach side effects affected 79.6% of people on CagriSema and 39.9% on placebo. They were mostly mild to moderate and short-lived.
  • Eloralintide: In the Phase 2 trial, nausea ranged from 11% to 64% across dose groups, compared with 14% on placebo. Fatigue was the other common side effect.
Safety Note

Eloralintide and cagrilintide are not approved medicines. Products sold online under these names, including vials labeled “for research use only,” are not FDA-approved drugs, and there is no way to know what is in them or how pure they are. Do not inject any product that is not prescribed to you and dispensed by a licensed pharmacy. Our guide on how to spot counterfeit medicines explains the warning signs.

Approved Options You Can Use Now

If you need help with weight or type 2 diabetes today, approved medicines are available with a prescription while the amylin drugs finish testing. Wegovy (semaglutide) and Zepbound (tirzepatide) are approved weight management medicines, and Mounjaro (tirzepatide) is approved for type 2 diabetes.

Wegovy

Semaglutide

Approved weight management medicine

You can order Wegovy through Pharma Giant, which fills U.S. prescriptions with licensed Canadian pharmacies.

Shop Wegovy How much Wegovy costs without insurance

Zepbound

Tirzepatide

Approved weight management medicine

Available through Pharma Giant with a valid prescription.

Shop Zepbound How much Zepbound costs without insurance

Mounjaro

Tirzepatide

Approved for type 2 diabetes

Available through Pharma Giant with a valid prescription.

Shop Mounjaro How much Mounjaro costs

Not sure which weight loss option fits? Read our Zepbound vs Wegovy comparison.

Whichever medicine you use, get it from a licensed pharmacy, take it exactly as prescribed, and talk with your prescriber before starting, stopping or switching treatment.

The bottom line

An amylin receptor agonist copies amylin, a fullness hormone your pancreas releases with insulin. The only approved one, pramlintide, treats diabetes. The new weekly versions, led by eloralintide and cagrilintide, have shown weight loss of around 20% in trials, but none is approved for weight loss yet.

If you want treatment now, approved options are available. With a valid prescription, we, at Pharma Giant, ship Zepbound to the U.S. from licensed Canadian pharmacies, and your prescriber can help you decide whether Zepbound, Wegovy or Mounjaro fits your needs.

Order Wegovy Through Pharma Giant

We fill U.S. prescriptions with licensed Canadian pharmacies.

Shop Wegovy

Frequently Asked Questions

No. Eloralintide is a selective amylin receptor agonist, not a GLP-1 drug. It copies the hormone amylin and acts on amylin receptors, while GLP-1 drugs such as semaglutide act on GLP-1 receptors. Lilly is also testing eloralintide together with tirzepatide.
Eloralintide is a lab-made peptide, a short chain of amino acids, designed to act like amylin for a full week after one injection. It was previously known as LY3841136. It is investigational and not approved for any use.
Eloralintide is being studied for adults with obesity or overweight, both on its own and with tirzepatide in people who also have type 2 diabetes. It is not approved, so it is not prescribed for any condition outside clinical trials.
No. Pramlintide (Symlin) is FDA-approved only for people with type 1 or type 2 diabetes who use mealtime insulin. Some people lost a small amount of weight in its diabetes trials, but it is not approved as a weight loss medicine.
Only in clinical trials for now. Combinations such as CagriSema (cagrilintide with semaglutide) and EloraTZP (eloralintide with tirzepatide) are being studied, but no amylin and GLP-1 combination was approved as of October 28, 2026. Never combine weight loss medicines on your own.
There is no approval date. Lilly’s Phase 3 trials of eloralintide are ongoing, and the company has not announced an FDA filing. Until a regulator approves it, eloralintide is only available to people enrolled in clinical trials. We, at Pharma Giant, are following the eloralintide trials closely. If it is approved by Health Canada and becomes available through the licensed Canadian pharmacies we work with, we plan to look into adding it to our catalog. Until then, check back on our blog for updates as new trial results come out.
  1. Eli Lilly and Company. Lilly’s selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight. November 6, 2025. View source
  2. Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2025;406(10520):2631-2643. PMID 41207310. View source
  3. Briere DA, Qu H, Lansu K, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept. Molecular Metabolism. 2025;102:102271. PMID 41109426. View source
  4. Eli Lilly and Company. Lilly’s EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes. September 30, 2026. View source
  5. Eli Lilly and Company. Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026. September 15, 2026. View source
  6. Hoogwerf BJ, Doshi KB, Diab D. Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vascular Health and Risk Management. 2008;4(2):355-362. PMID 18561511. View source
  7. U.S. National Library of Medicine, DailyMed. SymlinPen (pramlintide acetate) injection prescribing information. View source
  8. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2025;393:635-647. PMID 40544433. View source
  9. Novo Nordisk. Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management. December 18, 2025. View source
  10. Novo Nordisk. Novo’s CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial. September 21, 2026. View source
  11. 11. ClinicalTrials.gov. A study of LY3841136 (eloralintide) in participants with obesity or overweight (NCT06230523). View source